Suppr超能文献

复发性幕上恶性胶质瘤的化疗(II期研究)

[Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)].

作者信息

Afra Dénes, Sipos László, Vitanovics Dusán

机构信息

Országos Idegsebészeti Tudományos Intézet, Budapest.

出版信息

Ideggyogy Sz. 2002 Jan 20;55(1-2):38-44.

Abstract

At the Hungarian National Institute of Neurosurgery 73 recurrent supratentorial malignant tumours were treated by chemotherapy during the last ten years. Chemotherapy was applied after postoperative radiotherapy but in some cases following reoperation only. All cases were clinically and by CT or MRI verified recurrences. Forty-three patients received BCNU-DBD (dibromodulcitol) treatment (23 anaplastic astrocytoma--AA, and 20 glioblastoma multiforme--GM): day 1. BCNU 150 mg/sq.m. in i.v. infusion, day 2. dibromdulcitol 1000 mg/sq orally was given. This course was repeated every six weeks, altogether 2-8 times. Sixteen patients with AA responded with complete or partial regression but only 6 did with GM. Median survival was 14 and 7 months, the difference proved to be significant, p = 0.0091. PCV combination (procarbazine, CCNU, vincristine) was applied to 16 patients with AA and 14 cases with recurrent oligodendroglioma (O). Treatment started with vincristine 1.5 mg/sq.m. i.v. (2.0 mg maximum), the next day CCNU 100 mg/sq.m. was given, followed by procarbazine 60 mg/sq.m. on days 8-22. and finished by the same dose of vincristine on day 30. The course was repeated after one month, mostly six times. Six patients with AA did not respond; in cases of oligodendroglioma all but one responded with complete or partial improvement. It is remarkable that no significant difference was found between the survivals of BCNU-DBD or PCV treated AA patients. Chemotherapy of supratentorial malignant glioma recurrences with nitroso-ureas and their combination proved to be efficacious. It also seems, that in recurrent cases lower grade gliomas show better response rate than glioblastomas.

摘要

在匈牙利国家神经外科研究所,过去十年间对73例幕上复发性恶性肿瘤进行了化疗。化疗在术后放疗后进行,但在某些情况下仅在再次手术后进行。所有病例均经临床及CT或MRI证实为复发。43例患者接受了卡氮芥-二溴卫矛醇(BCNU-DBD)治疗(23例间变性星形细胞瘤——AA,20例多形性胶质母细胞瘤——GM):第1天,静脉输注卡氮芥150mg/平方米;第2天,口服二溴卫矛醇1000mg/平方米。该疗程每六周重复一次,共进行2至8次。16例AA患者出现完全或部分缓解,而GM患者仅有6例缓解。中位生存期分别为14个月和7个月,差异具有显著性,p = 0.0091。PCV联合方案(丙卡巴肼、洛莫司汀、长春新碱)应用于16例AA患者和14例复发性少突胶质细胞瘤(O)患者。治疗开始时静脉注射长春新碱1.5mg/平方米(最大剂量2.0mg),次日给予洛莫司汀100mg/平方米,随后在第8至22天给予丙卡巴肼60mg/平方米,并在第30天给予相同剂量的长春新碱结束治疗。该疗程一个月后重复,大多进行6次。6例AA患者无反应;少突胶质细胞瘤患者除1例外在所有病例中均出现完全或部分改善。值得注意的是,接受BCNU-DBD或PCV治疗的AA患者的生存期之间未发现显著差异。用亚硝基脲及其联合方案治疗幕上恶性胶质瘤复发被证明是有效的。似乎在复发病例中,低级别胶质瘤的反应率高于胶质母细胞瘤。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验